



# SciFinder<sup>®</sup> Searching for Science

## Знакомство с *SciFinder<sup>n</sup>*

ННГУ

Н. Новгород, 22.11.2019



**CAS**<sup>®</sup>

A DIVISION OF THE  
AMERICAN CHEMICAL SOCIETY



**SCIFINDER**<sup>®</sup>

A CAS SOLUTION



# Специалисты “индексаторы” CAS анализируют полные тексты публикаций, в которых фигурирует **вещество**

US 20070078189A1

(19) **United States**  
 (12) **Patent Application Publication** (10) Pub. No.: US 2007/0078189 A1  
 Sarshar (43) Pub. Date: Apr. 5, 2007

(54) **NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS**

(75) Inventor: **Sepher Sarshar**, Cardiff by the Sea, CA (US)

Correspondence Address:  
**DLA PIPER US LLP**  
 436 EXECUTIVE DRIVE  
 SUITE 1100  
 SAN DIEGO, CA 92121-2133 (US)

(73) Assignee: **Auspex Pharmaceuticals**, Vista, CA

(21) Appl. No.: **11/592,009**  
 (22) Filed: **Nov. 1, 2006**


**Related U.S. Application Data**

(63) Continuation-in-part of application No. PCT/US05/15366, filed on May 2, 2005.  
 (60) Provisional application No. 60/567,965, filed on May 3, 2004.

(52) U.S. CL. .... **514/090; 568/314; 568/326; 568/328**

(57) **ABSTRACT**

The present invention is directed to novel compounds according to formulae



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease treatment utilizing pharmaceutical compositions comprising these compounds. The compounds of this invention are novel therapeutic agents for the treatment of cancer, diabetes, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene

**CRYSTAL GROWTH AND DESIGN**  
 XXXX  
 VOL. XXX, NO. XX

**A Dynamic Microporous Metal–Organic Framework with BCT Zeolite Topology: Construction, Structure, and Adsorption Behavior**




Sheng Hu,<sup>1</sup> Jie-Peng Zhang,<sup>2</sup> Hao-Xiang Li,<sup>3</sup> Ming-Liang Tong,<sup>4\*</sup> Xiao-Ming Chen,<sup>4\*</sup> and Susumu Kitagawa<sup>1</sup>

*MOE Laboratory of Bioinorganic and Synthetic Chemistry/State Key Laboratory of Optoelectronic Materials and Technologies, School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou 510275, People's Republic of China, and Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Katata, Nishikyō-ku, Kyoto 613-8510, Japan*

Received June 30, 2007; Revised Manuscript Received August 14, 2007

**ABSTRACT:** A new microporous metal–organic framework (MOF) material [Ni<sub>4</sub>(dpa)(pyz)<sub>2</sub>(H<sub>2</sub>O)]·11H<sub>2</sub>O (1) with BCT zeolite topology has been hydrothermally synthesized. The framework components undergo dynamic structural transformation in response to removal and rebinding of the suitable guest molecules.

Microporous metal–organic framework (MOF) materials have received increasing attention mainly because of their potential application in adsorption, ion exchange, and catalysis, as well as intriguing architectures and topologies.<sup>1–2</sup> In particular, dynamic porous MOF materials retain crystallinity after some structural transformations, including stretching, rotational, “breathing”, and scissoring mechanisms, responding to external stimuli, which is essentially distinct from that of the rigid classical porous materials.<sup>3</sup> Those reversibly dynamic structural changes, being induced by removal/readsorption of guest molecules and/or caused by the removal/addition of ligands from/to the host framework itself, may be used for the accommodation and separation of specific molecules. However, it is still a challenge to control the pore size and chemical characteristics of the internal surface as well as decorate the topology of dynamic porous MOF materials.<sup>4</sup> A promising route to such materials is the rational choice of suitable inorganic compositions as secondary building units (SBUs) and flexible organic ligands as the spacers. 1,1'-Biphenyl-2,2'-dicarboxylic acid

**SCIFINDER<sup>®</sup>**  
 A CAS SOLUTION



**SCIFINDER<sup>®</sup>**  
 A CAS SOLUTION

Division of the American Chemical Society.  
 © 2007 American Chemical Society. All rights reserved.

# И добавляют **индексные термины** – ключевые слова и регистрационные номера веществ (**CAS RN**) согласно критериям **новизны и/или значимости**

Crystallography and Liquid Crystals (Section75-11)

## Concepts

Liquid crystals

chiral; study on chiral liq. crystals based on optical active isoamyl alc.

Esterification  
Phase transition  
Thermal stability

Heating  
Temperature

study on chiral liq. crystals based on optical active isoamyl alc.

## Substances

1403559-75-0P 🔍  
1403559-78-3P 🔍  
1403559-79-4P 🔍  
1403559-80-7P 🔍  
1403559-81-8P 🔍

study on chiral liq. crystals based on optical active isoamyl alc.

Properties; Synthetic preparation; Preparation

137-32-6 2-Methyl-butan-1-ol 🔍  
149-91-7 3,4,5-Trihydroxy-benzoic acid, reactions 🔍  
38289-28-0 🔍

study on chiral liq. crystals based on optical active isoamyl alc.

Reactant; Reactant or reagent



**SCIFINDER**<sup>®</sup>  
A CAS SOLUTION

vision of the American Chemical Society.  
2014 American Chemical Society. All rights reserved.


## Особенности контента CAS:

- **Независимый** выбор экспертом-индексатором стандартизированных ключевых слов (концепций), веществ, биологических объектов, процессов, материалов, реакций из первоисточников
- Информация анализируется экспертами в каждой **конкретной** области и владеющими **языком оригинала** публикации
- **Полнота** охвата и **взаимосвязанность** контента

# Ученые CAS обнаруживают существенные данные, такие как неявно описанные структуры, которые отсутствуют в других базах данных

Compound 34: Diisopropyl azodicarboxylate (DIAD) (1.20 mL, 6.08 mmol) was added to triphenylphosphine (1.60 g, 6.08 mmol) in THF (100 mL) at 0 °C. and was stirred for half an hour during which time the yellow solution became a paste. Compound 14 (2.58 g, 4.06 mmol) and p-nitrobenzoic acid (0.81 g, 4.87 mmol) were dissolved in THF (50 mL) and added to the paste. The resulted mixture was stirred at ambient temperature overnight. Water (100 mL) was added and the mixture was made slightly basic by adding NaHCO<sub>3</sub> solution followed by extraction with EtOAc (3x50 mL). The combined extracts were washed with brine once and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The desired product (2.72 g, 85% yield) was obtained as white powder after SiO<sub>2</sub> chromatography (Et<sub>2</sub>O/hexanes 1:2). m.p. 207-209 °C.; IR (KBr) 3434, 3056, 2940, 2868, 1722, 1608, 1529, 1489, 1448, 1345 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.30-8.26 (m, 2 H), 8.21-8.16 (m, 2 H), 7.46-7.42 (m, 6 H), 7.31-7.18 (m, 9 H) 5.33 (bs, 1 H), 4.02 (bs, 1 H), 3.90 (bs, 1 H), 3.09-2.97 (m, 2 H), 2.68 (td, J=14.95, 2.56 Hz, 1 H), 2.29-2.19 (m, 1 H), 2.07-1.06 (series of multiplets, 24 H), 1.01 (s, 3 H), 0.98 (d, J=6.6 Hz, 3 H), 0.70 (s, 3 H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 164.21, 150.56

CAS RN 203796-03-6



Absolute stereochemistry.



CAS®

A DIVISION OF THE  
AMERICAN CHEMICAL SOCIETY

# ПРИМЕР ПАТЕНТА

## CAS EXTRACTS MORE KNOWLEDGE THAN ANYONE ELSE

WO 2012135049

### Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans



7 концепций

138 соединений

4614 реакций


4 членов патентных семейств

3 цитируемых документа



# CAS ПОНИМАЕТ КАК ВЗАИМОСВЯЗАНЫ РАЗЛИЧНЫЕ ОБЛАСТИ ЗНАНИЯ

*1.4 млрд вершин  
14 млрд граней*



See Blog: [Innovation Drives Transformation](#)




**SciFINDER**<sup>®</sup>  
A CAS SOLUTION

**Стандартный** инструмент  
для более **500000** химиков по всему миру

# Что нам известно об этом соединении?

- ~6,730 References
- Reactions
- Commercial Sources
- Regulatory Information



**CAS Registry Number:** 501-36-0

C<sub>14</sub> H<sub>12</sub> O<sub>3</sub>

1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-  
 1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-, (E)-; 3,4',5-Stilbenetriol (7CI,8CI); Resveratrol (6CI); (E)-2-(3,5-Dihydroxyphenyl)-1-(4-hydroxyphenyl)ethene; (E)-3,4',5-Trihydroxystilbene; (E)-5-(p-Hydroxystyryl)resorcinol; (E)-Resveratrol; 3,4',5-Trihydroxy-trans-stilbene; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; CA 1201; Resveratrol P 5; Resvida; Vineatrol 20M; trans-3,5,4'-Trihydroxystilbene; trans-Resveratrol

Biological Properties	Value	Note
ADME (Absorption, Distribution, Metabolism, Excretion)	See full text	(2) CAS
Half-Life (Biological)	See full text	(9) CAS
LC50	See full text	(13) CAS
Minimum Inhibitory Concentration	See full text	(43) CAS

Lipinski and Related Properties	Value
Freely Rotatable Bonds	5
H Acceptors	3
H Donors	3
H Donor/Acceptor Sum	6
logP	3.024±0.267
Molecular Weight	228.24

Spectra Properties	Value
Carbon-13 NMR Spectrum	See spectrum
Proton NMR Spectrum	See spectrum

**Если это важно, это есть в SciFinder!**

# Базы данных входящие в SciFinder

<b>CAplus® – библиография</b> 10,000+ журналов (185 стран) патенты из 63 ведомств	45+ млн. ссылок (5,000 ежедневно), Рефераты и индексирование с 1802 г., цитаты с 1997–
<b>REGISTRY® – соединения</b> Органические и неорганич. структуры, последовательности	155+ млн. малых молекул (15,000 ежедневно), 67+ млн. последовательностей, 5,0+ млрд. свойств
<b>CASREACT® – реакции</b> Структурные диаграммы, детали	98+ млн. реакций и синтезов с 1840г.
<b>CHEMLIST® – регулируемая химия</b> REACH, EINECS, US. Gov/Fed. Register	348 k регулируемых соединений с 1979 г.
<b>CHEMCATS® – поставщики реактивов</b> Химические каталоги	Миллионы соединений от поставщиков, в том числе с уникальными CAS RNs
<b>MARPAT® – структуры Маркуша</b> 440k патентов, INPI с1961 г.	1,1+ млн.структур Маркуша (75 новых патентов ежедневно)
<b>MEDLINE – библиография</b> 5,200 биомедицинских журналов	24+ млн.библиографических NLM- ссылок с 1947 г.

## Преимущества SciFinder для пользователей в РФ:

- При производстве контента для SciFinder, CAS равномерно охватывает **все** области химии и смежных дисциплин
- Для пользователей в РФ важно знать, что публикуется и **патентуется** в **России**, а также быстро развивающихся **Китае, Корее и Индии**





*Новый продукт в семье SciFinder...*

## Объем доступной химической информации неуклонно растет!

- В некоторых случаях это рост по экспоненте
- Возрастает сложность, особенно в патентах
- Рост глобален

Information added to the CAS databases annually since 2000





Original publication languages in CAS databases



**К сожалению исследователи  
вынуждены тратить больше  
половины своего рабочего времени на  
поиск информации**

**И больше 50% времени поиска уходит  
на обработку первичных ответов от  
поисковых систем**



Source: CAS Global Customer Satisfaction Survey

## Почему понадобился новый продукт?

- Некоторым пользователям нужен не просто портал химических данных, а платформа, которая:
  - Дает что-то большее чем просто набор ответов;
  - Понимает логику исследователей и их способ постановки вопросов;
  - Быстро работает, тем самым высвобождает время для собственно исследований.
- Мнение клиентов за каждым решением. *Свыше 1,000 непосредственных интервью с учеными и дополнительно свыше тысячи опросов.*
- Ожидания от нового продукта:
  - Мощный, но легкий в использовании – *интуитивно понятный интерфейс*
  - Умный – *правильная интерпретация запросов пользователей*
  - Быстрый – *существенный рост скорости, экономия времени ученого*
  - Легкий переход пользователей обычного SciFinder на новую платформу



# Новый интерфейс, новые возможности поиска и многое другое!

Выбор  
поисковых  
опций

Удобная  
история

SciFINDER  
A CAS SOLUTION

Search

Search by Keyword, Substance Name, CAS RN, Patent Number, etc.

treatment of cancer

Advanced search

Recent Searches

March 28, 2017

11:55 AM

References: high temperature low density plasma (424K)

10:14 AM

References: Advanced Search (6)  
Organization: Memorial Sloan-Kettering Cancer Ctr.

March 27, 2017

5:33 PM

Reactions: As Drawn (9), Substructure (39)

Edit Drawing Remove

Edit Rerun Search

Edit Rerun Search

Edit Rerun Search

Одновременный поиск  
по тексту и структуре

# SciFinder<sup>n</sup> поддерживает touch screen и многостраничность!

The screenshot displays the SciFinder web interface. At the top, a browser window shows multiple tabs labeled 'SciFinder'. The main interface features a search bar with the text 'treatment of cancer' and a search icon. Below the search bar, there are navigation options like 'References' and 'Edit'. The main content area is titled 'References (3,103)' and shows a list of search results. The first result is 'Multikinase inhibitors: a new option for the treatment of thyroid cancer' by Gild, Matti L.; Bullock, Martyn; Robinson, Bruce G.; Clifton-Bligh, Roderick. The second result is 'sorafenib for the treatment of renal cancer' by Strumberg, Dirk. On the left side, there are filters for 'Structure Match' (As Drawn, Substructure) and 'Filter by' (Document Type, Language, Publication Year). A bar chart at the bottom left shows the distribution of results by publication year.

Одновременный  
поиск в нескольких  
вкладках/окнах

# Отбор наиболее релевантных вариантов ответов



References ▾ Glaucoma drugs

Draw



[Return to Home](#)

Filter by

^ Relevance

- Best (1,099)
- Good (254K)
- Fair (2.7M)

[Learn more about Relevance...](#)

^ Document Type

- Journal (2.4M)
- Patent (492K)
- Review (486K)
- Biography (933)
- Book (6,975)

[View All](#)

^ Language

- English (2.3M)
- Chinese (310K)
- Japanese (103K)

## References (3,014,727)

Sort: Relevance ▾ View: Full Abstract ▾

Substances ▾

Reactions ▾

Cited By ▾



Save

### Short-and long-term safety of glaucoma drugs

By: Schuman, Joel S.

Expert Opinion on Drug Safety (2002), 1(2), 181-194 | Language: English, Database: CPlus

[View Reference Detail](#)

**Abstract:** A review. Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative disorder. Patients with glaucoma may require long-term administration of intraocular pressure (IOP)-lowering medications. These medications belong to several classes of mols. including  $\beta$ -adrenergic blockers, cholinergic agents,  $\alpha$ -adrenergic agonists, carbonic anhydrase inhibitors, and ocular hypotensive lipids. Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use. The following review discusses the acute and long-term effects of commonly used IOP-lowering medications.

Full Text ▾

Substances (0)

Reactions (0)

Cited By (22)

Citation Map

### The inflow and outflow of anti-glaucoma drugs

By: Woodward, David F.; Gil, Daniel W.

Trends in Pharmacological Sciences (2004), 25(5), 238-241 | Language: English, Database: CPlus

[View Reference Detail](#)

**Abstract:** A review with references. The treatment of glaucoma by reducing intracocular pressure has relied traditionally on

Сортировка по релевантности



# Встроенный модуль для работы с патентами

Поиск  
химических  
структур в  
патенте

The screenshot displays the PATENTPAK interface. At the top, there is a navigation bar with 'PAGE 28 / 37', 'ZOOM' controls, and 'DOWNLOAD' options for PDF and PDF+. The main content area is titled 'CLAIMS' and lists six patent claims. A sidebar on the left, titled 'Key Substances in Patent', lists chemical structures with their CAS RNs. The structure for CAS RN 81624-55-7 is highlighted with a purple box. A tooltip for this structure is also highlighted with a purple box, showing the CAS Name: '1,2-Ethanediamine, N,N,N,N-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]-'. The text of claim 3, 'The pharmaceutical composition of claim 1, wherein the NPM inhibitor is gambogic acid.', is also highlighted with a purple box, and a purple location pin icon is placed next to the text 'NSC 48884'.

PATENTPAK<sup>®</sup>  
A CAS SOLUTION

PAGE 28 / 37 ZOOM DOWNLOAD  
PDF PDF+

Key Substances in Patent

CAS RN 2752-65-0

Analyst Markup Locations (1)  
Page 28

CAS RN 81624-55-7

CAS Name  
1,2-Ethanediamine,  
N,N,N,N-tetrakis[(6-  
methyl-1H-benzimidazol-  
2-yl)methyl]-

Substance Detail

Reactions (0)

Suppliers (15)

References (7)

Edit Structure


CLAIMS

What is claimed is:

1. A pharmaceutical composition, comprising:  
at least one NPM inhibitor;  
at least one anti-cancer agent; and  
a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein the NPM inhibitor is an siRNA that inhibits NPM expression.
3. The pharmaceutical composition of claim 1, wherein the NPM inhibitor is gambogic acid.
4. The pharmaceutical composition of claim 1, wherein the NPM inhibitor is NSC 48884.
5. The pharmaceutical composition of claim 1, wherein the anti-cancer agent is a target cancer therapy.
6. The pharmaceutical composition of claim 5, wherein the target cancer therapy is  
sorefenib.

Метки химических  
структур в тексте  
патента

# Встроенный модуль синтетических протоколов



[Stage 2]

Suppliers (7)

**Step 1**

Stage	Reagents	Cat
1	Potassium <i>tert</i> -butoxide	-
2	Potassium carbonate	-

CAS Reaction Number: 31

### Experimental Protocols

MethodsNow™ Experimental Procedure

**Products** 2-Pyridine-3,5,6-*d*<sub>3</sub>-carboxamide, 4-(4-aminophenoxy-2,3,5,6-*d*<sub>4</sub>)-*N*-(methyl-*d*<sub>3</sub>)-, Yield: 87%

**Reactants** 4-(Amino-*d*<sub>2</sub>)phen-2,3,5,6-*d*<sub>4</sub>-*o*-*d*  
2-Pyridine-3,5,6-*d*<sub>3</sub>-carboxamide, 4-chloro-*N*-(methyl-*d*<sub>3</sub>)-

**Reagents** Potassium *tert*-butoxide  
Potassium carbonate

**Solvents** Dimethylformamide

**Procedure**

1. Add potassium *tert*-butoxide (222 mg, 1.98 mmol) to a solution of *d*<sub>7</sub>-4-aminophenol (222 mg, 1.91 mmol; 97 atom % D (CDN Isotopes)) in DMF (2.0 mL).
2. Stir the reaction for 1 h.
3. Add a solution of 4-chloro-3,5,6-*d*<sub>3</sub>-*N*-(methyl-*d*<sub>3</sub>)picolinamide (305 mg, 1.73 mmol) in DMF (0.6 mL) via cannula to the mixture follow with a 0.6 mL DMF rinse.
4. Add K<sub>2</sub>CO<sub>3</sub> (129 mg, 0.935 mmol) to the mixture and heat the mixture to 80°C for 12 h.
5. Cool the reaction to room temperature.
6. Dilute the mixture with EtOAc and pour into a separatory funnel containing EtOAc and brine.
7. Wash the organic layer twice with brine.
8. Wash the combined aqueous solutions once with EtOAc.
9. Dry the combined organic solutions over Na<sub>2</sub>SO<sub>4</sub>.
10. Filter the mixture.
11. Concentrate the filtrate in vacuo.
12. Purify the residue on an ISCO instrument (0% to 90% EtOAc in hexanes) to afford 4-(4-aminophenoxy-*d*<sub>4</sub>)-3,5,6-*d*<sub>3</sub>-*N*-(methyl-*d*<sub>3</sub>)picolinamide.

**Transformation** Aromatic Substitution by Oxygen Nucleophiles

**Scale** milligram

**Characterization Data**

^ 2-Pyridine-3,5,6-*d*<sub>3</sub>-carboxamide, 4-(4-aminophenoxy-2,3,5,6-*d*<sub>4</sub>)-*N*-(methyl-*d*<sub>3</sub>)-



Mass Spectrum MS (M + H): 254.0

← Ключевые компоненты реакции

← Пошаговая инструкция

← Дополнительная информация

## Пример: полный синтез таксола



Кирьякос Николау – номинация на Нобелевскую премию по химии 2015

## Search

 All Substances Reactions **References** Suppliers

Search by Keyword, Substance Name, CAS RN, Patent Number, etc.



Draw




Use [Advanced search](#) for Author, Journal, or Organization

### Recent Search History

September 9, 2018

8:41 AM

 References: synthesis



As Drawn (2,746), Substructure (2,782)


[Edit](#)

[Rerun Search](#)



## В SciFinder<sup>n</sup> появился ретросинтез!

- Экспериментальный и теоретический ретросинтез
  - Альтернативные стратегии синтеза известных соединений
  - Предсказание стадий синтеза новых целевых молекул



Спасибо за внимание !

Ерохин Денис Валерьевич  
*derokhin@acs-i.org*

Connect with SciFinder



ACS International  
[www.cas.org](http://www.cas.org)



**CAS**<sup>®</sup>

A DIVISION OF THE  
AMERICAN CHEMICAL SOCIETY



**SCIFINDER**<sup>®</sup>

A CAS SOLUTION